Metrovacesa 将来の成長
Future 基準チェック /06
Metrovacesa利益と収益がそれぞれ年間2.1%と2.4%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に6.2% 1.7%なると予測されています。
主要情報
2.1%
収益成長率
1.71%
EPS成長率
| Real Estate 収益成長 | -1.0% |
| 収益成長率 | 2.4% |
| 将来の株主資本利益率 | 6.15% |
| アナリストカバレッジ | Low |
| 最終更新日 | 29 Apr 2026 |
今後の成長に関する最新情報
Recent updates
ナラティブの更新 • May 02
MVC: Slightly Higher Required Return And Rich P/E Will Constrain Future Upside
Analysts have kept their average price target for Metrovacesa broadly steady around €10.81, citing only slight shifts in discount rate, profit margin assumptions and future P/E expectations rather than any major change in the investment case. Valuation Changes Fair Value: The €10.81 fair value estimate is unchanged, indicating a stable central valuation point in the model.ナラティブの更新 • Apr 17
MVC: Higher Required Return And Rich P/E Will Pressure Future Returns
Analysts have kept their price target for Metrovacesa broadly unchanged at around €10.81 per share. The latest revisions reflect only very small model tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions, rather than any shift in their core view.ナラティブの更新 • Apr 03
MVC: Stable Assumptions And Discount Rate Tweaks Will Guide Future Returns
Analysts keep their Metrovacesa price target steady at €10.81, indicating largely unchanged assumptions on fair value, growth, margins, and future P/E, with only minor adjustments to discount rates and long-term expectations. Valuation Changes Fair Value: €10.81 per share is unchanged, suggesting the core view of what the stock is worth on a fundamental basis remains the same.ナラティブの更新 • Mar 20
MVC: Dividend Outlook And Revised Assumptions Will Shape Future Return Balance
Analysts now set their fair value estimate for Metrovacesa at €10.81 per share, up from €10.63. This reflects updated assumptions around the discount rate, revenue growth, profit margin and future P/E.
ナラティブの更新 • Mar 06
MVC: Lower Growth Assumptions And Elevated P/E Will Sustain Bearish View
Analysts have modestly lowered their price target on Metrovacesa to €9.30, citing updated assumptions for revenue growth, profit margins and the future P/E multiple, while keeping their fair value estimate unchanged at €9.30. Valuation Changes Fair Value: The fair value estimate is unchanged at €9.30 per share, indicating no revision to the overall valuation outcome.ナラティブの更新 • Feb 20
MVC: Dividend Outlook And Updated Assumptions Will Shape Future Return Balance
Analysts have slightly trimmed their fair value estimate for Metrovacesa from €10.83 to €10.63, citing updated assumptions around discount rates, expected revenue growth, margins and future P/E levels. Valuation Changes Fair Value: Trimmed slightly from €10.83 to €10.63 per share.ナラティブの更新 • Feb 06
MVC: Lower Discount Rate And High P/E Will Sustain Bearish View
Analysts have slightly raised their price target on Metrovacesa, citing updated assumptions for the discount rate, revenue growth, profit margins and future P/E, which together indicate a modestly higher fair value per share in euro terms. Valuation Changes Fair Value: unchanged at €9.30 per share.ナラティブの更新 • Jan 23
MVC: Dividend Reserve Plans And P/E Revisions Will Guide Cautious Outlook
Analysts have maintained their Metrovacesa fair value target at €9.30, citing a combination of updated assumptions that include slightly lower discount rates, higher revenue growth expectations, softer profit margins and a higher future P/E multiple in their latest models. What's in the News Metrovacesa has scheduled a Special and Extraordinary Shareholders Meeting for November 25, 2025, at 13:00 Central European Standard Time in Madrid, Spain (Key Developments).
ナラティブの更新 • Jan 08
MVC: Dividend Proposal At Extraordinary Meeting Will Support Bullish Thesis
Analysts have revised their price target on Metrovacesa from €11.80 to €13.10, citing updated assumptions around discount rates, revenue growth, profit margins, and the future P/E multiple. What's in the News Metrovacesa has scheduled a Special and Extraordinary Shareholders Meeting for November 25, 2025, at 13:00 Central European Standard Time in Madrid, Spain (calle principe de vergara 187, plaza de rodrigo uria, madrid) (Key Developments) The meeting agenda includes a proposal to discuss the distribution of dividends from freely distributable reserves, which may be relevant if you are focusing on potential cash returns to shareholders (Key Developments) The notice also refers to discussion of other matters at the meeting, indicating that additional shareholder topics could be addressed beyond dividends (Key Developments) Valuation Changes Fair Value Estimate was revised from €11.80 to €13.10, indicating a higher assessed value per share.ナラティブの更新 • Dec 24
MVC: Dividend Reserve Plans Will Shape A Cautious Medium-Term Outlook
Analysts have raised their price target on Metrovacesa from €6.50 to €9.30, citing higher expected revenue growth, improved profit margins, and a modestly richer future P/E multiple, despite a slightly higher discount rate. What's in the News Metrovacesa has called a special shareholders meeting for November 25, 2025, at 13:00 CET in Madrid to address key corporate matters.分析記事 • Dec 20
Metrovacesa S.A. (BME:MVC) Shares Could Be 23% Below Their Intrinsic Value Estimate
Key Insights Metrovacesa's estimated fair value is €11.52 based on 2 Stage Free Cash Flow to Equity Current share price...ナラティブの更新 • Dec 10
MVC: Dividend Decision And Revised Outlook Will Shape Balanced Return Prospects
Analysts have raised their price target on Metrovacesa from €9.81 to €10.83, citing a higher long term fair value despite moderating assumptions for revenue growth, profit margins and future earnings multiples. What's in the News Metrovacesa has scheduled a special and extraordinary shareholders meeting for November 25, 2025, at 13:00 Central European Standard Time in Madrid, Spain (Key Developments) The main agenda item for the upcoming meeting is the potential distribution of dividends from freely distributable reserves, which could affect shareholder returns policy (Key Developments) Shareholders will also address other unspecified matters at the meeting, leaving scope for additional corporate or capital structure decisions (Key Developments) Valuation Changes Fair Value: raised slightly from €9.81 to €10.83 per share, reflecting a modest uplift in long term valuation.分析記事 • Oct 02
Should You Think About Buying Metrovacesa S.A. (BME:MVC) Now?
Metrovacesa S.A. ( BME:MVC ), is not the largest company out there, but it had a relatively subdued couple of weeks in...分析記事 • Jul 25
Calculating The Fair Value Of Metrovacesa S.A. (BME:MVC)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Metrovacesa fair value estimate is €12.58 Metrovacesa's €10.15...分析記事 • May 04
Does Metrovacesa (BME:MVC) Have A Healthy Balance Sheet?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...分析記事 • Apr 12
Are Investors Undervaluing Metrovacesa S.A. (BME:MVC) By 40%?
Key Insights The projected fair value for Metrovacesa is €16.96 based on 2 Stage Free Cash Flow to Equity Metrovacesa...分析記事 • Feb 26
Metrovacesa's (BME:MVC) Performance Is Even Better Than Its Earnings Suggest
Even though Metrovacesa S.A.'s ( BME:MVC ) recent earnings release was robust, the market didn't seem to notice. We...
新しいナラティブ • Feb 19
Will Leverage Undersupplied Spanish Housing Market For Future Opportunities
High presales coverage allows focus on margin maximization, boosting future net margins amid an undersupplied market.分析記事 • Feb 07
Is It Time To Consider Buying Metrovacesa S.A. (BME:MVC)?
While Metrovacesa S.A. ( BME:MVC ) might not have the largest market cap around , it maintained its current share price...分析記事 • Dec 13
An Intrinsic Calculation For Metrovacesa S.A. (BME:MVC) Suggests It's 44% Undervalued
Key Insights Metrovacesa's estimated fair value is €16.39 based on 2 Stage Free Cash Flow to Equity Metrovacesa's €9.13...分析記事 • Sep 12
Estimating The Fair Value Of Metrovacesa S.A. (BME:MVC)
Key Insights The projected fair value for Metrovacesa is €9.93 based on 2 Stage Free Cash Flow to Equity Metrovacesa's...分析記事 • Aug 01
We Think Metrovacesa's (BME:MVC) Profit Is Only A Baseline For What They Can Achieve
The subdued stock price reaction suggests that Metrovacesa S.A.'s ( BME:MVC ) strong earnings didn't offer any...分析記事 • Jul 17
Is Now An Opportune Moment To Examine Metrovacesa S.A. (BME:MVC)?
While Metrovacesa S.A. ( BME:MVC ) might not have the largest market cap around , it saw significant share price...分析記事 • May 28
A Look At The Intrinsic Value Of Metrovacesa S.A. (BME:MVC)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Metrovacesa fair value estimate is €9.31 Current share price...分析記事 • May 01
We Think Metrovacesa (BME:MVC) Can Stay On Top Of Its Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...分析記事 • Mar 27
Is Now An Opportune Moment To Examine Metrovacesa S.A. (BME:MVC)?
While Metrovacesa S.A. ( BME:MVC ) might not have the largest market cap around , it received a lot of attention from a...分析記事 • Feb 12
A Look At The Fair Value Of Metrovacesa S.A. (BME:MVC)
Key Insights The projected fair value for Metrovacesa is €9.08 based on 2 Stage Free Cash Flow to Equity Current share...分析記事 • Nov 05
Does Metrovacesa (BME:MVC) Have A Healthy Balance Sheet?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...分析記事 • Jul 05
These 4 Measures Indicate That Metrovacesa (BME:MVC) Is Using Debt Extensively
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...分析記事 • May 21
Is Now An Opportune Moment To Examine Metrovacesa S.A. (BME:MVC)?
While Metrovacesa S.A. ( BME:MVC ) might not be the most widely known stock at the moment, it saw significant share...分析記事 • Apr 19
Estimating The Intrinsic Value Of Metrovacesa S.A. (BME:MVC)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Metrovacesa fair value estimate is €7.36 Current share price...分析記事 • Dec 02
Does Metrovacesa (BME:MVC) Have A Healthy Balance Sheet?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...分析記事 • Sep 23
Is It Too Late To Consider Buying Metrovacesa S.A. (BME:MVC)?
While Metrovacesa S.A. ( BME:MVC ) might not be the most widely known stock at the moment, it received a lot of...分析記事 • May 19
Estimating The Intrinsic Value Of Metrovacesa S.A. (BME:MVC)
Does the May share price for Metrovacesa S.A. ( BME:MVC ) reflect what it's really worth? Today, we will estimate the...分析記事 • Mar 05
Metrovacesa's (BME:MVC) Strong Earnings Are Of Good Quality
Metrovacesa S.A. ( BME:MVC ) just reported healthy earnings but the stock price didn't move much. We think that...分析記事 • Feb 16
Would Metrovacesa (BME:MVC) Be Better Off With Less Debt?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...分析記事 • Oct 05
Does Metrovacesa (BME:MVC) Have A Healthy Balance Sheet?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...分析記事 • Jul 02
Is Metrovacesa S.A. (BME:MVC) Worth €6.7 Based On Its Intrinsic Value?
Today we will run through one way of estimating the intrinsic value of Metrovacesa S.A. ( BME:MVC ) by projecting its...分析記事 • May 06
Is Metrovacesa (BME:MVC) Using Too Much Debt?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...分析記事 • Apr 06
Is Metrovacesa S.A. (BME:MVC) A Strong Dividend Stock?
Is Metrovacesa S.A. ( BME:MVC ) a good dividend stock? How can we tell? Dividend paying companies with growing earnings...分析記事 • Mar 15
Metrovacesa (BME:MVC) Share Prices Have Dropped 51% In The Last Three Years
Metrovacesa S.A. ( BME:MVC ) shareholders should be happy to see the share price up 12% in the last month. But that...分析記事 • Feb 16
Loss-Making Metrovacesa S.A. (BME:MVC) Set To Breakeven
We feel now is a pretty good time to analyse Metrovacesa S.A.'s ( BME:MVC ) business as it appears the company may be...分析記事 • Jan 26
When Should You Buy Metrovacesa S.A. (BME:MVC)?
Metrovacesa S.A. ( BME:MVC ), might not be a large cap stock, but it led the BME gainers with a relatively large price...分析記事 • Jan 05
A Look At The Fair Value Of Metrovacesa S.A. (BME:MVC)
In this article we are going to estimate the intrinsic value of Metrovacesa S.A. ( BME:MVC ) by taking the expected...分析記事 • Dec 14
If You Had Bought Metrovacesa's (BME:MVC) Shares A Year Ago You Would Be Down 24%
Metrovacesa S.A. ( BME:MVC ) shareholders should be happy to see the share price up 11% in the last month. But that...業績と収益の成長予測
| 日付 | 収益 | 収益 | フリー・キャッシュフロー | 営業活動によるキャッシュ | 平均アナリスト数 |
|---|---|---|---|---|---|
| 12/31/2028 | 757 | 62 | 198 | 125 | 2 |
| 12/31/2027 | 780 | 64 | 198 | 184 | 2 |
| 12/31/2026 | 745 | 66 | 183 | 187 | 2 |
| 12/31/2025 | 708 | 57 | 217 | 217 | N/A |
| 9/30/2025 | 632 | 27 | 124 | 124 | N/A |
| 6/30/2025 | 555 | -3 | 31 | 31 | N/A |
| 3/31/2025 | 604 | 6 | 63 | 63 | N/A |
| 12/31/2024 | 653 | 16 | 95 | 95 | N/A |
| 9/30/2024 | 651 | 17 | 75 | 75 | N/A |
| 6/30/2024 | 649 | 18 | 55 | 55 | N/A |
| 3/31/2024 | 616 | -15 | N/A | N/A | N/A |
| 12/31/2023 | 581 | -21 | 32 | 32 | N/A |
| 9/30/2023 | 535 | -68 | N/A | N/A | N/A |
| 6/30/2023 | 430 | -71 | 92 | 92 | N/A |
| 3/31/2023 | 454 | -38 | N/A | N/A | N/A |
| 12/31/2022 | 516 | -23 | 211 | 211 | N/A |
| 9/30/2022 | 529 | 25 | N/A | N/A | N/A |
| 6/30/2022 | 572 | 33 | 227 | 227 | N/A |
| 3/31/2022 | 575 | 31 | N/A | N/A | N/A |
| 12/31/2021 | 512 | 18 | 139 | 139 | N/A |
| 9/30/2021 | 413 | -71 | N/A | N/A | N/A |
| 6/30/2021 | 231 | -90 | -24 | -24 | N/A |
| 3/31/2021 | 138 | -160 | N/A | N/A | N/A |
| 12/31/2020 | 140 | -164 | -78 | -78 | N/A |
| 9/30/2020 | 164 | -87 | N/A | N/A | N/A |
| 6/30/2020 | 180 | -87 | -46 | -45 | N/A |
| 3/31/2020 | 214 | -6 | N/A | N/A | N/A |
| 12/31/2019 | 161 | -4 | -29 | -28 | N/A |
| 9/30/2019 | 206 | 0 | N/A | -15 | N/A |
| 6/30/2019 | 220 | 5 | N/A | 18 | N/A |
| 3/31/2019 | 211 | -11 | N/A | 21 | N/A |
| 12/31/2018 | 190 | -9 | N/A | 35 | N/A |
| 9/30/2018 | 103 | -14 | N/A | 147 | N/A |
| 6/30/2018 | 70 | -31 | N/A | -19 | N/A |
| 3/31/2018 | 34 | -34 | N/A | -38 | N/A |
| 12/31/2017 | 28 | -39 | N/A | -27 | N/A |
| 9/30/2017 | 29 | -55 | N/A | -172 | N/A |
| 12/31/2016 | 21 | -21 | N/A | 21 | N/A |
| 12/31/2015 | 36 | 64 | N/A | -62 | N/A |
アナリストによる今後の成長予測
収入対貯蓄率: MVCの予測収益成長率 (年間2.1% ) は 貯蓄率 ( 2.7% ) を下回っています。
収益対市場: MVCの収益 ( 2.1% ) Spanish市場 ( 11.6% ) よりも低い成長が予測されています。
高成長収益: MVCの収益は増加すると予測されていますが、大幅には増加しません。
収益対市場: MVCの収益 ( 2.4% ) Spanish市場 ( 6.4% ) よりも低い成長が予測されています。
高い収益成長: MVCの収益 ( 2.4% ) 20%よりも低い成長が予測されています。
一株当たり利益成長率予想
将来の株主資本利益率
将来のROE: MVCの 自己資本利益率 は、3年後には低くなると予測されています ( 6.2 %)。
成長企業の発掘
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/22 02:07 |
| 終値 | 2026/05/22 00:00 |
| 収益 | 2025/12/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Metrovacesa S.A. 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。22
| アナリスト | 機関 |
|---|---|
| Ignacio Romero | Banco de Sabadell. S.A. |
| null null | Banco de Sabadell. S.A. |
| Mariano Miguel Hidalgo | Banco Santander |